TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12221218

Group type: EXPERIMENTAL
Intervention: Phylloquinone-fortified oil (377 +/- 46 micro g/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Broccoli diet (417 +/- 45 micro g/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Phylloquinone-fortified oil
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 36
Study: 10457877

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (1 mL bolus of bupivacaine 0.25% followed by continuous infusion of 10 mL over 24 h)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia (10 mL bolus of bupivacaine 0.25% followed by 2 mL h-1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia
Number of subjects: 102

Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia
Number of subjects: 102
Study: 7872388

Group type: EXPERIMENTAL
Intervention: Topical aldose reductase inhibitor (CT-112)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (same preparation without the inhibitor)
Number of subjects: 39
Study: 2010880

Group type: EXPERIMENTAL
Intervention: Poet condition (authorial intentions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer condition (no authorial intentions)
Number of subjects: 0
Study: 6275788

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (all doses)
Number of subjects: 45
Study: 31845845

Group type: EXPERIMENTAL
Intervention: Deep learning model for predicting enhancing lesions on unenhanced MRI scans.
Number of subjects: 1008
Study: 30003336

Group type: EXPERIMENTAL
Intervention: Sustained-release β-alanine (SR)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Rapid-release β-alanine (RR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 39
Study: 28218406

Group type: EXPERIMENTAL
Intervention: Glue (Histoacryl®)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Sutures (non-absorbable polypropylene)
Number of subjects: 370
Study: 25488303

Group type: EXPERIMENTAL
Intervention: Vestipitant (4-36 mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 130
Study: 23802771

Group type: EXPERIMENTAL
Intervention: IFC 1 kHz
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IFC 4 kHz
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo IFC
Number of subjects: 150
Study: 22101886

Group type: EXPERIMENTAL
Intervention: 300 mg DHA and 42 mg EPA daily for 3 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Without DHA
Number of subjects: 120
Study: 19691714

Group type: EXPERIMENTAL
Intervention: Parent-training intervention
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (single workshop)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Retention rates
Number of subjects: 384
Study: 17533492

Group type: EXPERIMENTAL
Intervention: Oral isotretinoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral tetracycline plus topical adapalene
Number of subjects: 0
Study: 15013339

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 37
Study: 11772906

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous peritoneal insulin infusion (CPII)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CSII (using ELISA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CPII (using ELISA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of AIA formation between CSII and CPII
Number of subjects: 24
Study: 9694103

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg every 24 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.5 mg/kg every 8 hours
Number of subjects: 50
Study: 8127332

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5 percent)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Betamethasone (5.7 mg)
Number of subjects: 41
Study: 2771809

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 356238

Group type: EXPERIMENTAL
Intervention: 900 mg/day proquazone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 500 mg/day naproxen
Number of subjects: 40
Study: 31864581

Group type: EXPERIMENTAL
Intervention: Arthroscopic suprapectoral biceps tenodesis (ASPBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Open subpectoral biceps tenodesis (OSPBT)
Number of subjects: 75
Study: 30756451

Group type: EXPERIMENTAL
Intervention: Stratacel® (novel silicone-based wound dressing)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aquaphor® (standard of care)
Number of subjects: 20
Study: 28961833

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 483
Study: 25874370

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo stretching control
Number of subjects: 41
Study: 23977072

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study: 22846542

Group type: EXPERIMENTAL
Intervention: Internet-based brief personalized feedback intervention (n=476)
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Internet-based personalized brief advice intervention (n=450)
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Nonintervention control group (n=454)
Number of subjects: 1380
Study: 19416946

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with oestradiol plus noretisterone acetate
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (vitamin D3 and calcium supplementation without HRT)
Number of subjects: 88
Study: 17350965

Group type: EXPERIMENTAL
Intervention: Webster‐Stratton Incredible Years basic parenting programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 116
Study: 15226325

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus Paclitaxel 175 mg/m² (AT)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² plus Cyclophosphamide 600 mg/m² (AC)
Number of subjects: 275
Study: 11432650

Group type: EXPERIMENTAL
Intervention: Outpatient, subacute rehabilitation at home (n = 90)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual outpatient follow-up (n = 90)
Number of subjects: 180
Study: 9555954

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/day)
Number of subjects: 8
Study: 7889227

Group type: EXPERIMENTAL
Intervention: Nonparametric rank methods (e.g., Wilcoxon rank sum test, Wilcoxon signed rank test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extensions for crossover studies comparing more than two treatments
Number of subjects: 0
Study: 3265921

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pethidine (Control)
Number of subjects: 18
Study: 30231024

Group type: EXPERIMENTAL
Intervention: ARV community delivery model
Number of subjects: 2172

Group type: COMPARATOR
Intervention: Standard of care (facility-based care)
Number of subjects: 2172
Study: 28546013

Group type: COMPARATOR
Intervention: Conventional group (Group C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Endotracheal tube assisted group (Group ET)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope group (Group MG)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Head in the lateral position group (Group L)
Number of subjects: 200
Study: 26469308

Group type: EXPERIMENTAL
Intervention: Balance game training for 5 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group recording levels of physical activity
Number of subjects: 82
Study: 23751136

Group type: EXPERIMENTAL
Intervention: Added training and technical support in trial communities
Number of subjects: 8092

Group type: COMPARATOR
Intervention: Regular prevention efforts supported by national alcohol and drug action plans in control communities
Number of subjects: 8092
Study: 21596925

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4,000 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1,200 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18942491

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 17220049

Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol, applied twice daily for 52 weeks
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol, applied twice daily for 8 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: 0.5% timolol, applied twice daily for 8 weeks
Number of subjects: 196
Study: 12692112

Group type: EXPERIMENTAL
Intervention: D19S246 locus; significant differences in allele and genotype distributions
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group; 100 controls in initial screening and 63 controls in follow-up
Number of subjects: 239
Study: 11124552

Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25 (Monocryl)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Glycomer 631 (Biosyn)
Number of subjects: 183
Study: 8956759

Group type: EXPERIMENTAL
Intervention: sICAM‐1 in sera
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: sVCAM‐1 in sera
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: soluble L‐selectin in sera
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: sICAM‐1 in ELF
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: sVCAM‐1, soluble E‐selectin, and soluble L‐selectin in ELF
Number of subjects: 19
Study: 1372660

Group type: EXPERIMENTAL
Intervention: Localized hyperthermia treatment (43 +/- 0.5C, 6 sessions)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham procedure (no radio frequency power applied)
Number of subjects: 68
Study: 2951800

Group type: EXPERIMENTAL
Intervention: Duovent (200 micrograms of fenoterol and 80 micrograms of ipratropium bromide)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reproterol (1 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (two puffs)
Number of subjects: 16
Study: 30012361

Group type: EXPERIMENTAL
Intervention: Baseline cTnI measurement
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 48-72 hour cTnI measurement
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 30 day cTnI measurement
Number of subjects: 900
Study: 26342053

Group type: EXPERIMENTAL
Intervention: 5% O2
Number of subjects: 147

Group type: COMPARATOR
Intervention: 20% O2
Number of subjects: 147
Study: 24895001

Group type: EXPERIMENTAL
Intervention: Educational intervention (10 hours educational program, followed by on demand support by phone)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1018
Study: 22704111

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism rs9810233
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism rs1920201
Number of subjects: 528
Study: 20553136

Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with 1:100,000 epinephrine/sodium bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unbuffered 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study: 18711169

Group type: EXPERIMENTAL
Intervention: PITX2 DNA methylation
Number of subjects: 399

Group type: COMPARATOR
Intervention: Established prognostic factors (tumor size, grade, and age)
Number of subjects: 399
Study: 16551364

Group type: EXPERIMENTAL
Intervention: 2-dimensional guided M-mode echo measurements
Number of subjects: 20
Study: 14700373

Group type: EXPERIMENTAL
Intervention: Schematic scene condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Taxonomic grid condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Schematic grid condition
Number of subjects: 30
Study: 10723150

Group type: EXPERIMENTAL
Intervention: Losartan (cozaar, MSD, USA) 25 mg/day for 48 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Basic medication with nitrates, diuretic (on demand), digoxin, and aspirin
Number of subjects: 116
Study: 10155875

Group type: EXPERIMENTAL
Intervention: Antenatal care procedures (including screening tests)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domiciliary midwifery service
Number of subjects: 0
Study: 1330411

Group type: EXPERIMENTAL
Intervention: Balanced diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Protein diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fat diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study: 3970769

Group type: EXPERIMENTAL
Intervention: IAC-CPR
Number of subjects: 291

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 291
Study: 31348204

Group type: EXPERIMENTAL
Intervention: Radiomic method using texture analysis software Mazda3.3
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Random forest model
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Support vector machine model
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neural network model
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Groups based on median of GCS score, NIHSS score, and maximum diameter of hematoma
Number of subjects: 120
Study: 28574985

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation treatment (MRT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 122
Study: 25550339

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2-3 g/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) 0.06-0.1 mg/kg/day
Number of subjects: 150
Study: 23670167

Group type: EXPERIMENTAL
Intervention: Trabucco technique
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Valenti technique
Number of subjects: 162

Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 162

Group type: COMPARATOR
Intervention: Lichtenstein, Trabucco, and Valenti techniques
Number of subjects: 162
Study: 22331646

Group type: EXPERIMENTAL
Intervention: Processed tomato product
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-tomato alternative
Number of subjects: 25
Study: 19289319

Group type: EXPERIMENTAL
Intervention: Bed rest (48 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ambulatory activity (48 hours)
Number of subjects: 12
Study: 17618324

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (0.454% stabilized stannous fluoride/sodium hexametaphosphate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dentifrice (negative control)
Number of subjects: 0
Study: 15229333

Group type: EXPERIMENTAL
Intervention: Prepregnancy BMI
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: BMI of 28
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: BMI of 36
Number of subjects: 439
Study: 11529904

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Allergen challenge
Number of subjects: 26
Study: 9736592

Group type: EXPERIMENTAL
Intervention: Moderate-intensity warfarin (INR, 2.0 to 2.5) plus aspirin
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR, 1.5) plus aspirin
Number of subjects: 506

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 506
Study: 7520497

Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment for three to six months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17
Study: 3278190

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30447688

Group type: EXPERIMENTAL
Intervention: Initiation of mental healthcare in participants with poor MH (9% of participants) who did not receive mental healthcare at baseline.
Number of subjects: 5970

Group type: EXPERIMENTAL
Intervention: Cessation of mental healthcare in participants with good MH (66% of participants) who received mental healthcare at baseline.
Number of subjects: 5970

Group type: COMPARATOR
Intervention: Odds ratio for initiation of mental healthcare based on MH screening status.
Number of subjects: 5970

Group type: COMPARATOR
Intervention: Odds ratio for cessation of mental healthcare based on MH screening status.
Number of subjects: 5970
Study: 28468620

Group type: EXPERIMENTAL
Intervention: VB-001
Number of subjects: 168

Group type: COMPARATOR
Intervention: ZPTO shampoo
Number of subjects: 168
Study: 26272452

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2 % + methylprednisolone 1 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ropivacaine + steroid
Number of subjects: 120

Group type: COMPARATOR
Intervention: ropivacaine 0.2 % or placebo
Number of subjects: 120
Study: 23735723

Group type: EXPERIMENTAL
Intervention: Insulin sensitization (IS) therapy
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Insulin-providing (IP) therapy
Number of subjects: 1479
Study: 21168231

Group type: EXPERIMENTAL
Intervention: Active Body Control (ABC) Program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 70
Study: 19404608

Group type: EXPERIMENTAL
Intervention: GAD-alum 500 microg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GAD-alum 4 microg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GAD-alum 20 microg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GAD-alum 100 microg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16509763

Group type: EXPERIMENTAL
Intervention: Immediate-release glipizide 5mg (Glynase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended-release glipizide 5mg (Glynase) XL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucotrol XL
Number of subjects: 0

Group type: COMPARATOR
Intervention: New formulation developed in the laboratory (GLPF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended-release glipizide formulations
Number of subjects: 0
Study: 15366326

Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 2.2 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 4.4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 8.8 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 17.6 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 20
Study: 10904511

Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg twice daily (n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 26
Study: 9290985

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 10
Study: 8363025

Group type: EXPERIMENTAL
Intervention: Fiberoptic intubation (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laryngoscopy with topical anaesthesia (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laryngoscopy without topical anaesthesia (group 3)
Number of subjects: 30
Study: 3521259

Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 31780337

Group type: EXPERIMENTAL
Intervention: Subscapularis tenotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 100
Study: 31140192

Group type: EXPERIMENTAL
Intervention: Rome IV criteria for functional constipation
Number of subjects: 951

Group type: COMPARATOR
Intervention: Rome III criteria for functional constipation
Number of subjects: 951
Study: 28522130

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1,600 IU and calcium carbonate 1,000 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Calcium carbonate alone
Number of subjects: 150
Study: 26094330

Group type: EXPERIMENTAL
Intervention: Patients with inflammatory bowel diseases
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy persons), N=13
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patients with inflammatory bowel diseases and Control group
Number of subjects: 16
Study: 24041231

Group type: EXPERIMENTAL
Intervention: TAU and telephone monitoring and counseling (TMC)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: TAU and TMC plus incentives (TMC+)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 321
Study: 20952244

Group type: EXPERIMENTAL
Intervention: Multi-modal treatment program (MMT) including heat, Van den Akker manual therapy, stretching, and a return to running program.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise therapy (ET) including a home-based ET and a structured return to running program with instruction from a sports physical therapist.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both MMT and ET
Number of subjects: 0
Study: 18647656

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Montelukast (Mk)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16535795

Group type: EXPERIMENTAL
Intervention: ActivSkin therapy group
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (vash oil gauze)
Number of subjects: 9
Study: 14528620

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 10764174

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Facemask and Oral Airway (FM‐OA)
Number of subjects: 49
Study: 8836300

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia group (SH group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycemia group (non-SH group)
Number of subjects: 28
Study: 1461472

Group type: EXPERIMENTAL
Intervention: propofol + fentanyl in air/O2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: isoflurane + fentanyl in air/O2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: propofol + fentanyl in N2O/O2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: isoflurane in N2O/O2
Number of subjects: 100